Aspirin in Alzheimer’s Disease: Increased Risk of Intracerebral Hemorrhage: Cause for Concern?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background and Purpose— In a randomized controlled trial in Alzheimer’s disease (AD), we found a higher number of intracerebral hemorrhages (ICHs) in patients randomized to aspirin treatment. Here, we evaluate the literature on the risk of ICH as a complication in patients with AD treated with aspirin. Methods— Systematic review and comparison of the occurrence of events over time between the aspirin and control group in each trial using Cox regression analysis. Estimated hazard ratios (HRs) were combined in a pooled HR. Results— Two randomized controlled trials on aspirin for AD were found. In the Evaluation of Vascular Care in Alzheimer’s Disease (EVA) trial (conducted in our center), 4.6% of patients in the group receiving a multicomponent treatment that included aspirin had an ICH (3/65; 95% confidence interval [CI], 1.0 to 12.9) versus 0% in the control group (0/58; 95% CI, 0 to 6.2). In the Aspirin in Alzheimer’s Disease (AD2000) trial, these proportions were, respectively, 2.6% (4/156; 95% CI, 0.7 to 6.4) and 0% (0/154; 95% CI, 0 to 2.4). The pooled proportion of ICHs in the aspirin group is 3.2% (7/221; 95% CI, 1.3 to 6.4) versus 0% in the control group (0/212; 95% CI, 0 to 1.7). The pooled HR for an ICH in AD patients using aspirin is 7.63 (95% CI, 0.72 to 81.00; P =0.09). Conclusions— Although the number of cases in both trials is small, our findings suggest that aspirin use in AD might pose an increased risk of ICH, whereas it has no effect on cognition. If there is an unequivocal cardiovascular indication for aspirin, it should not be withheld in AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232
Cited by
van der Flier, W. M., Skoog, I., Schneider, J. A., Pantoni, L., Mok, V., Chen, C. L. H., & Scheltens, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.3 · Cited by 594
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“In vitro experiments on LPS-treated BV2 cells revealed that AT-LxA4 inhibits NFkB signaling pathway and NADPH oxidase activity, hence reducing proinflammatory cytokines and reactive oxygen species production, respectively, as potential mechanisms to explain its anti-inflammatory action (Wang et al., 2011; Wu et al., 2…”
BackgroundInfluentialSmith, E. E., Saposnik, G., Biessels, G. J., Doubal, F. N., Fornage, M., Gorelick, P. B., Greenberg, S. M., Higashida, R. T., Kasner, S. E., & Seshadri, S. (2017) · Stroke · doi:10.1161/str.0000000000000116 · Cited by 404
Cerebral Amyloid Angiopathy: Emerging Concepts
Yamada, M. (2015) · Journal of Stroke · doi:10.5853/jos.2015.17.1.17 · Cited by 367
Wardlaw, J. M., Makin, S. J., Valdés Hernández, M. C., Armitage, P. A., Heye, A. K., Chappell, F. M., Muñoz‐Maniega, S., Sakka, E., Shuler, K., Dennis, M. S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.006 · Cited by 260
METACOHORTS Consortium, Dichgans, M., Wardlaw, J., Smith, E., Zietemann, V., Seshadri, S., Sachdev, P., Biessels, G. J., Fazekas, F., Benavente, O., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.004 · Cited by 101
“For example, randomized trials of aspirin in patients with AD observed rates of intracerebral hemorrhage that were much higher than those in people without AD [30].”
Cerebral Microbleeds as a Biomarker in Alzheimer’S Disease? A Review in The Field
Shams, S., & Wahlund, L.-O. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.101 · Cited by 32
Metadata
- Authors
- Thoonsen, H., Richard, E., Bentham, P., Gray, R., van Geloven, N., De Haan, R. J., Van Gool, W. A., & Nederkoorn, P. J.
- Venue
- Stroke
- Published
- 2010-11
- Volume
- 41
- Issue
- 11
- Pages
- 2690-2692
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2126266889
- Cited by
- 58
- References
- 6
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.